Literature DB >> 799563

Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study.

G Muiesan, B Magnani, E Agabiti-Rosei, C Alicandri, E Ambrosioni, N Miele.   

Abstract

1. The effects of timolol alone and in combination with a fixed dose of hydrochlorothiazide and amiloride have been studied in a double-blind, controlled study in fifty-four patients with mild to moderate essential hypertension. 2. After a 4 weeks placebo period patients were randomly assigned to enter groups receiving timolol alone (group A), hydrochlorothiazide + amiloride (group B) or timolol + hydrochlorothiazide + amiloride (group C). Each treatment was carried out for 6 weeks. 3. The use of timolol (10 mg), hydrochlorothiazide (25 mg) and amiloride (2-5 mg) in a combination tablet given twice daily gave better control of blood pressure in patients with mild to moderate essential hypertension than did equivalent dosages of timolol alone or of hydrochlorothiazide and amiloride. 4. Clinical and laboratory side effects were minimal.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 799563     DOI: 10.1042/cs051529s

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN: 0144-4107


  3 in total

1.  Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: a double-blind multicentre controlled study.

Authors:  A Lechi; S Pomari; R Berto; P Buniotto; A Parrinello; F Marini; L Cogo; A Tomasi; G Baretta
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  Timolol and bendrofluazide in the management of hypertension in general practice.

Authors:  D Wheatley
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.

Authors:  George L Bakris; Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.